tamibarotene has been researched along with delanzomib in 1 studies
| Studies (tamibarotene) | Trials (tamibarotene) | Recent Studies (post-2010) (tamibarotene) | Studies (delanzomib) | Trials (delanzomib) | Recent Studies (post-2010) (delanzomib) |
|---|---|---|---|---|---|
| 198 | 10 | 105 | 37 | 1 | 31 |
| Protein | Taxonomy | tamibarotene (IC50) | delanzomib (IC50) |
|---|---|---|---|
| Neutrophil elastase | Homo sapiens (human) | 3.55 | |
| Cathepsin G | Homo sapiens (human) | 1.0618 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 3.5 | |
| Proteasome subunit beta type-1 | Homo sapiens (human) | 0.031 | |
| Chymase | Homo sapiens (human) | 3.53 | |
| Proteasome subunit beta type-8 | Homo sapiens (human) | 0.003 | |
| Proteasome subunit beta type-9 | Homo sapiens (human) | 0.001 | |
| Proteasome subunit beta type-5 | Homo sapiens (human) | 0.0033 | |
| Proteasome subunit beta type-10 | Homo sapiens (human) | 0.01 | |
| Proteasome subunit beta type-2 | Homo sapiens (human) | 3.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonovolias, ID; Chatzopoulou, M; Demopoulos, VJ; Nicolaou, I; Tsiftsoglou, AS; Vizirianakis, IS | 1 |
1 review(s) available for tamibarotene and delanzomib
| Article | Year |
|---|---|
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia; Multipotent Stem Cells; Neoplastic Stem Cells; Pharmacogenetics | 2010 |